{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T05:17:20Z","timestamp":1777785440521,"version":"3.51.4"},"reference-count":81,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Am Psychiatr Nurses Assoc"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>OBJECTIVE: This article presents proven, promising, and potential therapeutic uses for cannabidiol (CBD) in the treatment of psychiatric and neurologic conditions and diseases. It presents popular, but scientifically unproven health and therapeutic claims of CBD supporting the beneficial homeostatic effects of the intrinsic or endogenous cannabinoid system. It includes a review of cannabinoid pharmacology; it compares properties and the legal status of CBD and THC (delta 9-tetrahydrocannabinol) as well as the hemp and marijuana varieties of Cannabis, and it reviews the historic 2018 U.S. Food and Drug Administration approval of Epidiolex, an oral solution of cannabidiol for two rare treatment-resistant childhood epilepsies, as the first Cannabis-derived drug. METHOD: We reviewed literature on cannabidiol, CBD, the endocannabinoid neuropharmacology system, and hemp and marijuana varieties of Cannabis sativa. RESULTS: The proven and promising medical uses and deficiencies of unproven health claims for CBD, legal implications for Cannabis-derived drugs, and comparisons of CBD and THC and hemp and marijuana are summarized objectively with pertinent references. CONCLUSION: CBD and CBD and THC combinations have potential to provide safe, effective therapy for several psychiatric and neurologic conditions and diseases. However, such achievement will require a uniform standard of CBD purity and strength, and corroboration from adequately large and rigorously controlled clinical research studies.<\/jats:p>","DOI":"10.1177\/1078390320929410","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T05:03:31Z","timestamp":1591419811000},"page":"447-457","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6200-5160","authenticated-orcid":false,"given":"Marian","family":"Newton","sequence":"first","affiliation":[{"name":"Marian Newton, PhD, PMHNP-BC, PMHCNS, ANEF, Eleanor Wade Custer School of Nursing, Shenandoah University, Winchester, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Newton","sequence":"additional","affiliation":[{"name":"David W. Newton, BS Pharm, PhD, FAPhA, Pharmacy Professor Emeritus, Shenandoah University, Winchester, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"key":"bibr1-1078390320929410","unstructured":"American Psychological Association. (2017). Prolonged exposure (PE). https:\/\/www.apa.org\/ptsd-guideline\/treatments\/prolonged-exposure"},{"key":"bibr2-1078390320929410","unstructured":"Americans for Safe Access. (2019). Patient\u2019s guide to CBD. https:\/\/www.safeaccessnow.org\/patientscbd"},{"key":"bibr3-1078390320929410","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312457586"},{"key":"bibr4-1078390320929410","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.6"},{"key":"bibr5-1078390320929410","doi-asserted-by":"crossref","unstructured":"Black N., Stockings E., Campbell G., Tran L.T., Zagic D., Hall W.D., Farrell M., Degenhardt L. (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis. Lancet Psychiatry, 6(12), 995-1010. https:\/\/doi.org\/10.1016\/S2215-0366(19)30401-8","DOI":"10.1016\/S2215-0366(19)30401-8"},{"key":"bibr6-1078390320929410","doi-asserted-by":"crossref","unstructured":"Boggs D. L., Surti T., Gupta A., Gupta S., Niciu M., Pittman B., Schnakenberg Martin A. M., Thurnauer H., Davies A., D\u2019Souza D. C., Ranganathan M. (2018). The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology, 235(7), 1923-1932. https:\/\/doi.org\/10.1007\/s00213-018-4885-9","DOI":"10.1007\/s00213-018-4885-9"},{"key":"bibr7-1078390320929410","doi-asserted-by":"crossref","unstructured":"Bonn-Miller M., Loflin M.J.E., Thomas B.F., Marcu J.P., Hyke T., Vandrey R. (2017). Labeling accuracy of cannabidiol extracts sold online. Journal of the American Medical Association, 318(17), 708-1709. https:\/\/doi.org\/10.1001\/jama.2017.11909","DOI":"10.1001\/jama.2017.11909"},{"issue":"3","key":"bibr8-1078390320929410","first-page":"180","volume":"42","author":"Bridgeman M.B.","year":"2017","journal-title":"Pharmacology and Therapeutics"},{"key":"bibr9-1078390320929410","unstructured":"Cadena A. (2019a). Is CBD Legal? The legal status of CBD in 2019. https:\/\/cbdorigin.com\/is-cbd-legal\/"},{"key":"bibr10-1078390320929410","unstructured":"Cadena A. (2019b). Hemp vs Marijuana: The difference explained. https:\/\/cbdorigin.com\/hemp-vs-marijuana\/"},{"key":"bibr11-1078390320929410","unstructured":"CDC Health Alert Network. (2019). Severe pulmonary disease associated with using e-cigarette products. https:\/\/emergency.cdc.gov\/han\/han00421.asp"},{"key":"bibr12-1078390320929410","unstructured":"Congressional Research Service. (2019). Defining hemp: A fact sheet. https:\/\/fas.org\/sgp\/crs\/misc\/R44742.pdf"},{"key":"bibr13-1078390320929410","doi-asserted-by":"crossref","unstructured":"Corroon J. M., Mischley L. K., Sexton M. (2017). Cannabis as a substitute for prescription drugs\u2014A cross-sectional study. Journal of Pain Research, 10, 989-998. https:\/\/doi.org\/10.2147\/JPR.S134330","DOI":"10.2147\/JPR.S134330"},{"key":"bibr14-1078390320929410","doi-asserted-by":"crossref","unstructured":"Crippa J. A. S., Derenusson G. N., Ferrari T. B., Wichert-Ana L., Duran F. L. S., Martin-Santos R., Sim\u00f5es M. V., Bhattacharyya S., Fusar-Poli P., Atakan Z., Santos Filho A., Freitas-Ferrari M. C., McGuire P. K., Zuardi A. W., Busatto G. F., Hallack J. E. C. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology, 25(1), 121-130. https:\/\/doi.org\/10.1177\/0269881110379283","DOI":"10.1177\/0269881110379283"},{"key":"bibr15-1078390320929410","unstructured":"Daley B. (2019). CBD: Rising star or popular fad? The Conversation. https:\/\/theconversation.com\/cbd-rising-star-or-popular-fad-110146"},{"key":"bibr16-1078390320929410","doi-asserted-by":"crossref","unstructured":"Donvito G., Nass S. R., Wilkerson J. L., Curry Z. A., Shurman L. D., Kinsey S. G., Lichtman A. H. (2018). The endogenous cannabinoid system: A budding source of targets for treating inflammatory and neuropathic Pain. Neuropsychopharmacology, 43(1), 52-79. https:\/\/doi.org\/10.1038\/npp.2017.204","DOI":"10.1038\/npp.2017.204"},{"key":"bibr17-1078390320929410","unstructured":"Dorbian I. (2019). CBD market could pull in $16 billion by 2025, says study. https:\/\/www.forbes.com\/sites\/irisdorbian\/2019\/03\/12\/cbd-market-could-pull-in-16-bln-by-2025-says-study\/#2275f0613efd"},{"key":"bibr18-1078390320929410","unstructured":"Drugs.com. (2018) Epidiolex. https:\/\/www.drugs.com\/epidiolex.html"},{"key":"bibr19-1078390320929410","doi-asserted-by":"crossref","unstructured":"Elms L., Shannon S., Hughes S., Lewis N. (2019). Cannabidiol in the treatment of post-traumatic stress disorder: A case series. Journal of Alternative and Complementary Medicine, 25(4), 392-397. https:\/\/doi.org\/10.1089\/acm.2018.0437","DOI":"10.1089\/acm.2018.0437"},{"key":"bibr20-1078390320929410","unstructured":"Fiorillo S. (2019). Is CBD oil legal in 2019? State-by-state and future legality. https:\/\/www.thestreet.com\/lifestyle\/health\/is-cbd-oil-legal-14802001"},{"key":"bibr21-1078390320929410","doi-asserted-by":"crossref","unstructured":"Fraser G. A. (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neuroscience and Therapeutics, 15(1), 84-88. https:\/\/doi.org\/10.1111\/j.1755-5949.2008.00071.x","DOI":"10.1111\/j.1755-5949.2008.00071.x"},{"key":"bibr22-1078390320929410","doi-asserted-by":"crossref","unstructured":"Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterk\u00f6tter J., Piomelli D. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology, 29(11), 2108-2114. https:\/\/doi.org\/10.1038\/sj.npp.1300558","DOI":"10.1038\/sj.npp.1300558"},{"key":"bibr23-1078390320929410","unstructured":"Grinspoon P. (2018). Cannabidiol (CBD)\u2014What we know and what we don\u2019t. https:\/\/www.health.harvard.edu\/blog\/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476"},{"key":"bibr24-1078390320929410","unstructured":"Gupta S. (2013). Weed: A CNN special report. https:\/\/www.cnn.com\/2013\/08\/08\/health\/gupta-changed-mind-marijuana\/index.html"},{"key":"bibr25-1078390320929410","unstructured":"Gupta S. (2019). Weed 5: the CBD craze. Dr. Sanjay Gupta on medical marijuana: We are in an age of wisdom, but also an age of foolishness. https:\/\/www.cnn.com\/2019\/09\/27\/health\/weed-5-cbd-craze-gupta\/index.html"},{"key":"bibr26-1078390320929410","unstructured":"GW Pharma, Ltd. (2015). Sativex product monograph. https:\/\/www.bayer.ca\/omr\/online\/sativex-pm-en.pdf"},{"key":"bibr27-1078390320929410","unstructured":"GW Pharmaceuticals, PLC. (2018). EPIDIOLEX\u00ae (cannabidiol) Oral Solution\u2014The first FDA-approved Plant-derived Cannabinoid Medicine\u2014Now Available by Prescription in the U.S. http:\/\/ir.gwpharm.com\/news-releases\/news-release-details\/epidiolexr-cannabidiol-oral-solution-first-fda-approved-plant"},{"key":"bibr28-1078390320929410","unstructured":"GW Pharmaceuticals, PLC. (2019). Sativex. https:\/\/www.gwpharm.com\/healthcare-professionals\/sativex"},{"key":"bibr29-1078390320929410","volume":"60","author":"Harrar S.","year":"2019","journal-title":"AARP Bulletin"},{"key":"bibr30-1078390320929410","unstructured":"Hollander E. (2019). Cannabidivarin (CBDV) vs. placebo in children with autism spectrum disorder (ASD). ClinicalTrials.gov Identifier: NCT03202303. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03202303"},{"key":"bibr31-1078390320929410","doi-asserted-by":"crossref","unstructured":"Howlett A. C., Abood M. E. (2017). CB\n                      1\n                      & CB\n                      2\n                      receptor pharmacology. Advances in Pharmacology, 80, 169-206. https:\/\/doi.org\/10.1016\/bs.apha.2017.03.007","DOI":"10.1016\/bs.apha.2017.03.007"},{"key":"bibr32-1078390320929410","unstructured":"Hudak J. (2018). The Farm Bill, hemp legalization and the status of CBD: an explainer. https:\/\/www.brookings.edu\/blog\/fixgov\/2018\/12\/14\/the-farm-bill-hemp-and-cbd-explainer\/"},{"key":"bibr33-1078390320929410","unstructured":"Jaeger K. (2019). This is why federal agencies are warning employees about CBD. https:\/\/www.marijuanamoment.net\/this-is-why-federal-agencies-are-warning-employees-about-cbd\/"},{"key":"bibr34-1078390320929410","unstructured":"Jones G. (2019). GW Pharma\u2019s cannabis-based medicine to be tested in dementia. https:\/\/www.pmlive.com\/pharma_news\/gw_pharmas_cannabis-based_medicine_to_be_tested_in_dementia_1278436?SQ_DESIGN_NAME=2"},{"key":"bibr35-1078390320929410","unstructured":"Kaplan S. (2019). Cannabis companies push FDA to ease rules on CBD products. https:\/\/www.nytimes.com\/2019\/05\/31\/health\/cannabis-fda-regulate.html"},{"key":"bibr36-1078390320929410","unstructured":"Kubala J. (2018). 7 benefits and uses of CBD oil (plus side effects). https:\/\/www.healthline.com\/nutrition\/cbd-oil-benefits"},{"key":"bibr37-1078390320929410","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2017.19.3\/glafaye"},{"key":"bibr38-1078390320929410","doi-asserted-by":"crossref","unstructured":"Laprarie R. B., Bagher A. M., Kelly M. E., Denovan-Wright E. M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172(20), 4790-4805. https:\/\/doi.org\/10.1111\/bph.13250","DOI":"10.1111\/bph.13250"},{"key":"bibr39-1078390320929410","doi-asserted-by":"crossref","unstructured":"Leweke F. M. (2012). Anandamide dysfunction in prodromal and established psychosis. Current Pharmaceutical Design, 18(32), 5188-5193. https:\/\/doi.org\/10.2174\/138161212802884843","DOI":"10.2174\/138161212802884843"},{"key":"bibr40-1078390320929410","doi-asserted-by":"crossref","unstructured":"Leweke F. M., Piomelli D., Pahlisch F., Muhl D., Gerth C. W., Hoyer C., Klosterk\u00f6tter J., Hellmich M., Koethe D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry, 2(3), e94. https:\/\/doi.org\/10.1038\/tp.2012.15","DOI":"10.1038\/tp.2012.15"},{"key":"bibr41-1078390320929410","doi-asserted-by":"crossref","unstructured":"Lu H-C., Mackie K. (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry, 79(7), 516-525. https:\/\/doi.org\/10.1016\/j.biopsych.2015.07.028","DOI":"10.1016\/j.biopsych.2015.07.028"},{"key":"bibr42-1078390320929410","doi-asserted-by":"crossref","unstructured":"McGuire P., Robson P., Cubala W. J., Vasile D., Morrison P. D., Barron R., Taylor A., Wright S. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. American Journal of Psychiatry, 175(3), 225-231. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17030325","DOI":"10.1176\/appi.ajp.2017.17030325"},{"key":"bibr43-1078390320929410","doi-asserted-by":"crossref","unstructured":"Minichino A., Senior M., Brondino N., Zhang S. H., Godlewska B., Burnet P. W. J. Lennox B. (2019). Measuring disturbance of the endocannabinoid system in psychosis: a systematic review and meta-analysis. JAMA Psychiatry, 76(9), 914-923. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0970","DOI":"10.1001\/jamapsychiatry.2019.0970"},{"key":"bibr44-1078390320929410","unstructured":"National Cancer Institute. (2019). Cannabis and cannabinoids (PDQ\u00ae)\u2014Health professional version. https:\/\/www.cancer.gov\/about-cancer\/treatment\/cam\/hp\/cannabis-pdq"},{"key":"bibr45-1078390320929410","unstructured":"National Institute on Drug Abuse. (2019). Opioid overdose crisis. https:\/\/www.drugabuse.gov\/drugs-abuse\/opioids\/opioid-overdose-crisis"},{"key":"bibr46-1078390320929410","unstructured":"Natural Force. (2019). Hemp oil vs CBD oil: Everything you need to know. https:\/\/naturalforce.com\/blogs\/nutrition\/hemp-oil-vs-cbd-oil"},{"key":"bibr47-1078390320929410","doi-asserted-by":"crossref","unstructured":"Neumeister A., Normandin M.D., Peitrzak R.H., Piomelli D., Zheng M.Q., Gujarro-Anton Potenza M. N., Bailey C. R., Lin S. F., Najafzadeh S., Ropchan J., Henry S., Corsi-Travali S., Carson R. E., Huang Y. (2013). Elevated brain cannabinoid CB\n                      1\n                      receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular Psychiatry, 18(9), 1034-1040. https:\/\/doi.org\/10.1038\/mp.2013.61","DOI":"10.1038\/mp.2013.61"},{"key":"bibr48-1078390320929410","unstructured":"Nichols K. (2019). \u201cThe FDA is struggling\u201d: Former US Surgeon General Carmona on government\u2019s approach to CBD. https:\/\/hempindustrydaily.com\/former-us-surgeon-general-richard-carmona-talks-about-cbd-trend\/"},{"key":"bibr49-1078390320929410","doi-asserted-by":"crossref","unstructured":"Pacher P., Batkai S., Kunos G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389-462. https:\/\/doi.org\/10.1124\/pr.58.3.2","DOI":"10.1124\/pr.58.3.2"},{"key":"bibr50-1078390320929410","unstructured":"Paton C. (2019). THC overdose: Has first death from marijuana exposure been recorded in the United States? https:\/\/www.newsweek.com\/thc-overdose-death-marijuana-exposure-united-states-1442742"},{"key":"bibr51-1078390320929410","doi-asserted-by":"crossref","unstructured":"Pertwee R. G. (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. British Journal of Pharmacology, 156(3), 397-411. https:\/\/doi.org\/10.1111\/j.1476-5381.2008.00048.x","DOI":"10.1111\/j.1476-5381.2008.00048.x"},{"key":"bibr52-1078390320929410","doi-asserted-by":"crossref","unstructured":"Perucca E. (2017). Cannabinoids in the treatment of epilepsy: hard evidence at last? Journal of Epilepsy Research, 7(2), 61-76. https:\/\/doi.org\/10.14581\/jer.17012","DOI":"10.14581\/jer.17012"},{"key":"bibr53-1078390320929410","unstructured":"Petkovic B. (2019). Hemp oil vs CBD oil: How different are they exactly? https:\/\/loudcloudhealth.com\/hemp-oil-vs-cbd-oil\/"},{"issue":"5","key":"bibr54-1078390320929410","first-page":"12","volume":"18","author":"Pierre J. M.","year":"2019","journal-title":"Current Psychiatry"},{"key":"bibr55-1078390320929410","unstructured":"Project CBD. (2019). What is CBD? https:\/\/www.projectcbd.org\/cbd-101\/what-is-cbd"},{"key":"bibr56-1078390320929410","unstructured":"Rawls B. (2019). The CBD oil: Everything you need to know. https:\/\/rawlsmd.com\/health-articlesciencebehind\/science-behind-cbd-everything-want-know"},{"key":"bibr57-1078390320929410","unstructured":"Royal Society of Chemistry. (2019a). CBD. http:\/\/www.chemspider.com\/Chemical-Structure.24547.html"},{"key":"bibr58-1078390320929410","unstructured":"Royal Society of Chemistry. (2019b). (\u2212)-\u03b4-9-trans-Tetrahydrocannabinol. http:\/\/www.chemspider.com\/Chemical-Structure.15266.html"},{"key":"bibr59-1078390320929410","unstructured":"Rudd J. (2018). CBD vs THC\u2014What are the main differences? https:\/\/www.analyticalcannabis.com\/articles\/cbd-vs-thc-what-are-the-main-differences-297486"},{"key":"bibr60-1078390320929410","unstructured":"Sadock B. J., Sadock V. A., Ruiz P. (2017). Kaplan & Sadock\u2019s comprehensive textbook of psychiatry (10th ed.; Vol. 1; pp. 1303-1312). Walters Kluwer."},{"key":"bibr61-1078390320929410","doi-asserted-by":"crossref","unstructured":"Samuelsson B. (2000). The discovery of the leukotrienes. American Journal of Respiratory and Critical Care Medicine, 61(Suppl. 1), S2-S6. https:\/\/doi.org\/10.1164\/ajrccm.161.supplement_1.ltta-1","DOI":"10.1164\/ajrccm.161.supplement_1.ltta-1"},{"key":"bibr62-1078390320929410","unstructured":"Sanders L. (2019). The CBD boom is way ahead of the science. https:\/\/www.sciencenews.org\/article\/cbd-product-boom-science-research-hemp-marijuana"},{"issue":"6","key":"bibr63-1078390320929410","first-page":"30","volume":"227","author":"Sides H.","year":"2015","journal-title":"National Geographic"},{"key":"bibr64-1078390320929410","unstructured":"Tess\u00e9ra Naturals. (2019). Hemp oil vs CBD oil. https:\/\/tesseranaturals.com\/hemp-oil-vs-cbd-oil\/"},{"key":"bibr65-1078390320929410","unstructured":"United Nations Office on Drugs and Crime. (2017). World drug report. https:\/\/www.unodc.org\/wdr2017\/field\/WDR_2017_presentation_lauch_version.pdf"},{"key":"bibr66-1078390320929410","volume-title":"United States Pharmacopeia 42\u2013National Formulary 37","author":"United States Pharmacopeial Convention, Inc.","year":"2019"},{"key":"bibr67-1078390320929410","doi-asserted-by":"crossref","unstructured":"Urits I., Borchart M., Hasegawa M., Kochanski J., Orhurhu V., Viswamath O. (2019). An update of current Cannabis-based pharmaceuticals in pain medicine. Pain and Therapy, 8(1), 41-51. https:\/\/doi.org\/10.1007\/s40122-019-0114-4","DOI":"10.1007\/s40122-019-0114-4"},{"key":"bibr68-1078390320929410","unstructured":"U.S. Code Title 21-Food and Drugs, Chapter 9-Federal Food, Drug and Cosmetic Act\n                      . (2018). https:\/\/uscode.house.gov\/view.xhtml?path=\/prelim@title21\/chapter9&edition=prelim"},{"key":"bibr69-1078390320929410","unstructured":"U.S. Drug Enforcement Administration. (2018). Schedules of controlled substances: Placement in Schedule V of Certain FDA-approved drugs containing cannabidiol; corresponding change to permit requirements. https:\/\/www.federalregister.gov\/documents\/2018\/09\/28\/2018-21121\/schedules-of-controlled-substances-placement-in-schedule-v-of-certain-fda-approved-drugs-containing"},{"key":"bibr70-1078390320929410","unstructured":"U.S. Food and Drug Administration. (2006). Cesamet (nabilone) oral capsules full prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/018677s011lbl.pdf"},{"key":"bibr71-1078390320929410","unstructured":"U.S. Food and Drug Administration. (2018). Epidiolex (cannabidiol) oral solution full prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf"},{"key":"bibr72-1078390320929410","unstructured":"U.S. Food and Drug Administration. (2019). Remarks by Dr. Sharpless at the FDA public hearing on scientific data and information about products containing cannabis or cannabis-derived compounds. https:\/\/www.fda.gov\/news-events\/speeches-fda-officials\/remarks-dr-sharpless-fda-public-hearing-scientific-data-and-information-about-products-containing"},{"key":"bibr73-1078390320929410","unstructured":"U.S. Senate. (2018). Agriculture Improvement Act of 2018. https:\/\/www.agriculture.senate.gov\/imo\/media\/doc\/Agriculture%20Improvement%20Act%20of%202018.pdf"},{"key":"bibr74-1078390320929410","unstructured":"VA Office of Research and Development. (2019). Cannabidiol as an Adjunctive to prolonged exposure for the treatment of PTSD. ClinicalTrials.gov Identifier: NCT03518801. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03518801?term=cbd&cond=ptsd&draw=2&rank=1"},{"key":"bibr75-1078390320929410","unstructured":"Wan W. (2019). Many unanswered questions, concerns about CBD products, says FDA acting chief at first public hearing. https:\/\/www.washingtonpost.com\/business\/2019\/05\/31\/amid-flood-cbd-products-fda-holds-first-public-hearing-cannabis-extract\/?utm_term=.af68c83a1a7a"},{"key":"bibr76-1078390320929410","unstructured":"World Health Organization. (2016). The health and social effects of nonmedical cannabis use. https:\/\/www.who.int\/substance_abuse\/publications\/msbcannabis.pdf"},{"key":"bibr77-1078390320929410","unstructured":"World Health Organization. (2017). CANNABIDIOL (CBD) Pre-Review Report, Agenda Item 5.2. Thirty-ninth meeting. Geneva, November 6-10. https:\/\/www.who.int\/medicines\/access\/controlled-substances\/5.2_CBD.pdf"},{"key":"bibr78-1078390320929410","unstructured":"Wong C. (2019). CBD Oil: Benefits, uses, side effects, and safety. https:\/\/www.verywellhealth.com\/cbd-oil-benefits-uses-side-effects-4174562"},{"key":"bibr79-1078390320929410","first-page":"482","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"Yakish T. L.","year":"2011","edition":"12"},{"key":"bibr80-1078390320929410","doi-asserted-by":"crossref","unstructured":"Zou S., Kumar U. (2018). Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. International Journal of Molecular Sciences, 19(3), E833. https:\/\/doi.org\/10.3390\/ijms19030833","DOI":"10.3390\/ijms19030833"},{"key":"bibr81-1078390320929410","doi-asserted-by":"crossref","unstructured":"Zuardi A. W., Rodrigues N. P., Silva A. L., Bernardo S. A., Hallak J. E. C., Guimar\u00e3es F. S., Crippa J. A. S. (2017). Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Frontiers in Pharmacology, 8, 259. https:\/\/doi.org\/10.3389\/fphar.2017.00259","DOI":"10.3389\/fphar.2017.00259"}],"container-title":["Journal of the American Psychiatric Nurses Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078390320929410","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078390320929410","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078390320929410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:43:59Z","timestamp":1777491839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078390320929410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,6]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1177\/1078390320929410"],"URL":"https:\/\/doi.org\/10.1177\/1078390320929410","relation":{},"ISSN":["1078-3903","1532-5725"],"issn-type":[{"value":"1078-3903","type":"print"},{"value":"1532-5725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,6]]}}}